替格瑞洛治疗41例急性冠状动脉综合征患者的临床疗效被引量：63

Clinical effects of ticagrelor in 41 Chinese acute coronary syndrome patients

下载PDF

导出

摘要目的探讨替格瑞洛治疗急性冠状动脉综合征(ACS)患者的早期临床疗效及经验。方法回顾性分析2013年3月至2013年5月在东莞康华医院应用替格瑞洛的41例ACS患者在行经皮冠状动脉介入治疗(PCI)术前及术后临床有效性及安全性。结果所有患者服用替格瑞洛期间无重大不良心血管事件发生;出现1例主要出血事件(主要原因为股动脉穿刺处处理欠妥,可能与替格瑞洛无关),1例次要出血;3例呼吸困难,继续用药症状缓解;1例因心动过缓停用β阻滞剂。结论替格瑞洛的临床疗效确切,并且具有良好的安全性和耐受性。 Objective To observe the clinical treatment effect and summarize the clinical experience in using new antiplatelet agent,ticagrelor,in Chinese acute coronary syndrome（ ACS） patients. Methods Retrospective analysis using ticagrelor to treat 41 cases of ACS patients before and after PCI,and observe the clinical effectiveness and safety from March 2013 to May 2013 in Kanghua Hospital. Results 41 patients were given ticagrelor. There were no major adverse cardiovascular events happened; and no major bleeding events occurred. 3 cases presented dyspnea and 1 case had bradycardia who needed withdrawal of the drug. Conclusions The early using ticagrelor in Chinese ACS patients showed similar clinical effect consistent with the PLATO trials results. The side effect of dyspnea and bradycardia had lower rates than in the PLATO trials. In Chinese patients,ticagrelor seemed better clinical curative effect and more beneficial safety and tolerability.

作者朱永宏贾国良周妙朱遵平袁战军周小欧张新文夏天

机构地区东莞康华医院心血管内科

出处《中国介入心脏病学杂志》 2013年第6期374-376,共3页 Chinese Journal of Interventional Cardiology

关键词急性冠状动脉综合征替格瑞洛经皮冠状动脉介入治疗 ACS Ticagrelor PCI

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1Anderson SD,Shah NK,Yim J,et al.Efficacy and safety of ticagrelor:a reversible P2Y12 receptor antagonist.Ann Pharmacother,2010,44:524-537.
2Antman EM,Hand M,Armstrong PW,et al.2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2008,51:210-247.
3Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.J Am Coll Cardiol,2007,50:e1-e157.
4James S,Akerblom A,Cannon CP,et al.Comparison of ticagrelor,the first reversible oral P2Y(12) receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.Am Heart J,2009,157:599-605.
5Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.
6Serebruany VL,Stebbing J,Atar D.Dyspnoea after antiplatelet agents:the AZD6140 controversy.Int J Clin Pract,2007,61:529-533.
7Reynolds SM,Docherty R,Robbins J,et al.Adenosine induces a cholinergic tracheal reflex contraction in guinea pigs in vivo via an adenosine A1 receptor-dependent mechanism.J Appl Physiol (1985),2008,105:187-196.